WO2023021479 - A SYNERGISTIC POLY HERBAL FORMULATION FOR TREATING VIRAL INFECTIONS AND A PROCESS OF PREPARATION THEREOF
National phase entry is expected:
Publication Number
WO/2023/021479
Publication Date
23.02.2023
International Application No.
PCT/IB2022/057810
International Filing Date
19.08.2022
Title **
[English]
A SYNERGISTIC POLY HERBAL FORMULATION FOR TREATING VIRAL INFECTIONS AND A PROCESS OF PREPARATION THEREOF
[French]
FORMULATION SYNERGIQUE COMPRENANT PLUSIEURS PLANTES, DESTINÉE AU TRAITEMENT D'INFECTIONS VIRALES ET SON PROCÉDÉ DE PRÉPARATION
Applicants **
ALAKART BIOPHARMA INC.
347, Elizabeth Ave, Ste #200
Somerset, New Jersey 08873, US
Inventors
REDDY, Ramgopal
347, Elizabeth Ave, Ste #200
Somerset, New Jersey 08873, US
MUTHU, Hari
1st Floor, H. No.1-98-9/3/9 & 10, 25 &26, Sy.No.71(Part)
Madhapur
Hyderabad 500081, IN
Priority Data
202111022421
19.08.2021
IN
202111022422
19.08.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1027 | |
| EPO | Filing, Examination | 7060 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 3480 |
Total: 12765 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
, and a process of preparation thereof. The cost effective immune-supporting formulation is ideal for use during the maintenance phase of the treatment, following an initial viral load reduction phase in which it is used as an adjuvant to conventional anti-viral drug therapy. Additionally, this formulation is used for treating and prevention of COVID-19.[French]
, et un procédé de préparation associé. La formulation de soutien immunitaire économique est idéale pour une utilisation pendant la phase d'entretien du traitement, suite à une phase initiale de réduction de la charge virale dans laquelle elle est utilisée en tant qu'adjuvant pour une thérapie médicamenteuse antivirale classique. De plus, cette formulation est utilisée pour le traitement et la prévention du COVID-19.